XGN - Exagen Inc logo

XGN

Exagen Inc

Exagen Inc. develops and commercializes diagnostic tests under the AVISE brand for autoimmune and rheumatic diseases like lupus and rheumatoid arthritis. Its products assist healthcare providers in diagnosing and monitoring complex conditions through blood testing.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$524today

Score Overview

1 Year
Score
Net Growth5.15%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth6.83%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.8
Net Growth29.53%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth47.25%
Rev Trend80%
Revenue Consistencyโ€”
All Time
Score
Net Growth-57.19%
Net Trend43%
Net Income Consistency
Rev Growth76.10%
Rev Trend86%
Revenue Consistency

See the full market ranking โ†’

Exagen Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 41M to $ 66M and net income went from -$ 16M to -$ 19M. Revenue increased in 4 of those 5 years; net income in 3.

Exagen Inc currently holds a 5-year HDB Score of 5.8 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 6.59โ€”
1 Year2025-08-12
$ 9.56-31.07%
5 Years2021-08-12
$ 12.58-47.62%
All Time2019-09-19
$ 17.11-61.48%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 71M-$ 18M$ 24M
2025$ 66M-$ 19M$ 32M
2024$ 55M-$ 15M$ 22M
2023$ 52M-$ 23M$ 36M
2022$ 45M-$ 47M$ 62M
2021$ 48M-$ 26M$ 99M
2020$ 41M-$ 16M$ 57M
IPO2019$ 40M-$ 12M$ 72M

Explore beyond XGN

You're looking at Exagen Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies